Pacira BioSciences Inc. Common Stock (PCRX)

FairStock Score: 21/100 — RISKY

Key Financials

AI Analysis

AI-generated, general educational analysis — not personal investment advice.

Mr. Market is offering Pacira at $36.31 as of 2026-10-13, near its 52-week high of $36.46. The story is a turnaround: after a fiscal 2024 net loss of $99.6M, the company earned $7.0M in fiscal 2025 and $4.7M in fiscal Q2 2026. Revenue has been modest, rising from $675.0M in fiscal 2023 to $726.4M in fiscal 2025, with fiscal Q2 2026 revenue of $192.4M. That is not the profile of a wide-moat compounder, but non-opioid pain management has real clinical value and EXPAREL, ZILRETTA, and iovera give it a niche. Still, profitability is fragile: fiscal Q2 2026 net margin was only 2.42%, and FairStock's calculated ROE is 2.05% and ROCE 1.48%. The balance sheet is leveraged with D/E of 0.61, and FairStock's Altman Z-Score of 1.96 is not comforting. Free cash flow is the bright spot: $179.5M trailing, a 12.4% FCF yield. But at $36.31, FairStock calculates a P/E of 103.74, P/B of 2.15, and Graham Number of $11.53 — the price is far above the Graham value. The PEG of 0.53 looks cheap only because profit growth is rebounding from a loss; that is not durable evidence. With FairStock Score 21/100 and Lynch classified as a TURNAROUND because it returned to profit after a loss within the last three years, I would demand a much lower price or clear evidence that margins are moving toward historical levels before calling this a margin-of-safety investment.

In plain English: Pacira BioSciences sells non-opioid pain medicines and related devices to hospitals and doctors. The business has returned to profit recently, but profits are still thin and the company is not very efficient with its money. At the recent price, the shares look expensive compared with those profits, even though the company produces a good amount of cash.

The full AI analysis, bull and bear case and key monitorables are in FairStock Pro.

Data as of 2026-10-13 close · note generated 2026-10-15 · model deepseek-flash

Sources (SEC EDGAR): fiscal Q2 2026 10-Q (period ended 2026-06-30) · fiscal Q1 2026 10-Q (period ended 2026-03-31) · fiscal Q3 2025 10-Q (period ended 2025-09-30) · fiscal Q2 2025 10-Q (period ended 2025-06-30) · FY2025 10-K (period ended 2025-12-31) · FY2024 10-K (period ended 2024-12-31) · FY2023 10-K (period ended 2023-12-31)

Fundamentals from company filings and market-data providers; prices are end-of-day, not real-time. AI-generated analysis is general and educational — not personal investment advice. Scoring methodology · Score test · Disclaimer